Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 17/20 | 0.51 |
| ▸ | PDE4A | P27815 | 1/20 | 0.51 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.51 |
| ▸ | HPGDS | O60760 | 1/20 | 0.43 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5747354 | 0.93 | PDE4B (0.51) | PDE4BPDE4APDE4DHPGDSSSTR4 | |
| SCHEMBL5745282 | 0.91 | PDE4B (0.53) | PDE4BPDE4APDE4DHPGDSCYP3A4 | |
| SCHEMBL5744700 | 0.89 | PDE4B (0.53) | PDE4BPDE4APDE4DHPGDSCYP3A4 | |
| SCHEMBL5748482 | 0.87 | PDE4B (0.52) | PDE4BPDE4APDE4DHPGDS | |
| SCHEMBL5747017 | 0.84 | PDE4B (0.50) | PDE4BPDE4APDE4DCYP3A4 | |
| SCHEMBL5746330 | 0.82 | PDE4B (0.49) | PDE4BPDE4APDE4DHPGDSCYP3A4 | |
| SCHEMBL5744020 | 0.81 | PDE4B (0.50) | PDE4BPDE4APDE4DHPGDS | |
| SCHEMBL5840085 | 0.81 | PDE4B (0.56) | PDE4BPDE4APDE4DCYP3A4 | |
| SCHEMBL5840082 | 0.81 | PDE4B (0.56) | PDE4BPDE4APDE4DCYP3A4 | |
| SCHEMBL5747094 | 0.80 | PDE4B (0.47) | PDE4BPDE4APDE4DHPGDSSSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040038991-A1 | Imidazolyl-cyclic acetals | AVENTIS PHARMA LIMITED (GB) | 2004-02-26 | — | — | US | claimed |
| US-6602877-B1 | Imidazolyl-cyclic acetals | AVENTIS PHARMA LIMITED (GB) | 2003-08-05 | — | — | US | claimed |
| EP-0988301-B1 | IMIDAZOLYL-CYCLIC ACETALS | AVENTIS PHARMA LTD (GB) | 2006-08-09 | — | — | EP | disclosed |
| EP-1651635-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | Pfizer Limited (GB) | 2006-05-03 | — | — | EP | disclosed |
| US-6989395-B2 | Imidazolyl-cyclic acetals | AVENTIS PHARMA LIMITED (GB) | 2006-01-24 | — | — | US | disclosed |
| WO-2005009989-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | PFIZER LIMITED (GB) | 2005-02-03 | — | — | WO | disclosed |
| WO-2005009989-A1 | NICOTINAMIDE DERIVATIVES USEFUL AS PDE4 INHIBITORS | PFIZER LIMITED (GB) | 2005-02-03 | — | — | WO | disclosed |
| US-20050020587-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | PFIZER INC | 2005-01-27 | — | — | US | disclosed |
| US-6602877-B1 | Imidazolyl-cyclic acetals | AVENTIS PHARMA LIMITED (GB) | 2003-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050020587-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | PDE4A, PDE4B, PDE4D | PDE4B 2/4885PDE4A 1/4885PDE4D 3/4885 |
| US-20040038991-A1 | Imidazolyl-cyclic acetals | CBR1, LBR, CBR3 | PDE4B 4304/4885PDE4A 4576/4885PDE4D 4547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.